Блог им. gtcapital

SPY продолжает вчерашнюю коррекцию

Ближайший уровень поддержки по SPY – 195.00 уровень сопротивления – 196.00

Блог им. gtcapital: SPY продолжает вчерашнюю коррекцию

LRCX продажа от 75

WLP покупка от 119

DWRE продажа ниже 58

Gapping up/down: SIMO +15% and CAMP +7% after earnings, FEYE +6% after new partnerships; GMCR +2% on upgrade at GS; SODA and TCS -15% after earnings/guidance; LVS -3% after dg Price: null Change: null

Gapping up
In reaction to strong earnings/guidance: SIMO +14.9%, CAMP +7.2%, ISCA +4.9%, NLNK +1.9%, IDT +0.6%

Select Ebola related names showing strength: CMRX +3.9%, TKMR +3.4%, LAKE +2.8%

Select metals/mining stocks trading higher: IGLD +2.5%, IAG +0.8%, CDE +0.8%, SVM +0.6%

Other news: GTAT +15% (modest retracement following yesterday's massive decline), MAGS +15% (receives $8.2 mln of new orders; majority of the contracts are for expansions, changes and upgrades of existing homeland security installations in Israel), XCO +10.6% (announces sale of interests in Compass Production Partners), BCLI +9% (FDA grants fast track designation to NurOwn for the treatment of ALS), OXGN +8.3% (announced that data from the Phase 2 GOG186I study of fosbretabulin in combination with bevacizumab will be presented on November 9 at the International Gynecologic Cancer Society), GSAT +7.1% (issues statement in response to Kerrisdale Capital presentation), FEYE +5.8% (FireEye and SingTel partner to launch first managed defense solution; also, announced targeted attack protection for the Apple (AAPL) platform), BCRX +2.4% (announces late breaker presentation of OPuS-1 Phase 2 Trial results at the 23rd EADV Congress will be present Oct 11), ADHD +2.3% (after yesterday's 57% decline), ACHN +1.8% (disclosed it entered into a Master Security Agreement for a $1,000,000 Capital Expenditure Line of Credit), SBLK +1.6% (collected $8.016 mln from the sale of its claim against PAN OCEAN), REGN +1.3% (EYLEA (aflibercept) Injection received FDA approval for macular edema following retinal vein occlusion), PSTI +1.3% (wins cell therapy patent case in Europe; European Patent Office confirms validity of amended claims )

Analyst comments: ADHD +2.3% (upgraded to Outperform at FBR Capital), NDLS +2.1% (upgraded to Buy from Hold at Jefferies), AUY +2.1% (upgraded to Neutral from Underweight at HSBC Securities), GMCR +1.9% (initiated with a Buy at Goldman), KPTI +1.1% (initiated with a Outperform at Wedbush), IP +1.1% (upgraded to Buy from Neutral at BofA/Merrill), CCK +0.7% (upgraded to Outperform from Neutral at Macquarie)

Gapping down
In reaction to disappointing earnings/guidance: SODA -15.1%, TCS -14.6%, EZPW -13.6%, CBK -11.8%, AEGN -9.3%, AGCO -8.7%

M&A news: RIO -1% (issues statement regarding press speculation surrounding Glencore (GLNCY))

Notable EU names showing weakness: ORAN -2.2%, DB -2.1%, NOK -2%, NBG -1.8%, RCL -1.2%, CCL -1.1%, AZN -1.1%, UBS -1.1%, LYG -0.8%, CS -0.8%

Other news: KOS -6.1% (announces secondary public offering of 15 mln common shares), BBEP -5.3% (announces public offering of 14 mln common units), END -5.3% (announced the appointment of a Chief Restructuring Officer), IBIO -4.7% (files for sale of up to 23,418,172 shares of common stock by Aspire Capital Fund), CNHI -4.3% (in sympathy with AGCO earnings), KCAP -3.8% (commences 3 mln share public offering), DYN -2.1% (launched 22.5 mln share common stock and 4 mln share mandatory convertible preferred stock offerings), NRP -2% (prices 8.5 mln common units at $12.02 per common unit), OTIV -1.6% (filed for $50 mln mixed securities shelf offering), BUD -1.6% (still checking), MBLY -1.4% (cont weakness), NUS -1% (following afternoon strength on volume)

Analyst comments: LVS -3.1% (downgraded to Hold from Buy at Deutsche Bank), URI -2.7% (downgraded to Neutral from Buy at BofA/Merrill), DE -2.6% (downgraded to Underperform from Neutral at BofA/Merrill), SAN -1.4% (downgraded to Reduce from Neutral at Nomura), CMI -1.3% (downgraded to Neutral from Buy at BofA/Merrill), ATI -1.2% (downgraded to Hold from Buy at KeyBanc Capital Mkts), USB -0.8% (downgraded to Mkt Perform from Strong Buy at Raymond James )

Оригинал статьи: gtstocks.com/analytics-07-10-2014.html

0 комментариев

Оставить комментарий